<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36790">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01869621</url>
  </required_header>
  <id_info>
    <org_study_id>AKF-383</org_study_id>
    <secondary_id>2012-005179-15</secondary_id>
    <nct_id>NCT01869621</nct_id>
  </id_info>
  <brief_title>Study of Metformin Pharmacogenetics in Twins</brief_title>
  <official_title>The Relation Between Heritability and the Trough Concentration of Metformin in Plasma Under Steady-state in Twins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Denmark: The National Committee on Health Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trough concentration of metformin will be examined in monozygotic and dizygotic twins.
      Current twin study will determine the total weight of genetics on the trough concentration
      of metformin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Heritability</measure>
    <time_frame>After 6 days of metformin treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The trough concentrations of metformin in twin pairs will be used to determine the effect of heritability on metformin trough concentrations. This will give insight to the weight that genetic factors have on metformin pharmacokinetics at steady-state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single nucleotide polymorphisms (SNPs)</measure>
    <time_frame>After 6 days treatment with metformin</time_frame>
    <safety_issue>No</safety_issue>
    <description>The effect of SNPs on trough metformin concentration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 days treatment with metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>6 days treatment with metformin to steady-state</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-40 years

          -  Both twins has to be included

          -  Dizygotic twin pairs has to be same sex

          -  Informed consent given

          -  Healthy condition

        Exclusion Criteria:

          -  Chronical/daily alcohol abuse

          -  Hypersensitivity to metformin

          -  Ingestion of drugs containing topiramate or x-ray contrast fluids

          -  For women: Positive pregnancy test/breastfeeding at the beginning of the trial. No
             use of safe anticonceptives
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Pharmacology</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tore B. Stage, MSc Pharm</last_name>
      <phone>+45 6550 3678</phone>
      <email>tstage@health.sdu.dk</email>
    </contact>
    <investigator>
      <last_name>Per Damkier, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 31, 2013</lastchanged_date>
  <firstreceived_date>May 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Tore B. Stage</investigator_full_name>
    <investigator_title>MSc Pharm</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
